Sector portfolio · Private equity · United States
MPM Capital's Biotech portfolio
MPM Capital has backed 32 Biotech startups in rounds we track, $4.0B between them, shown by the stage each has reached. The best-funded is 23andme.
32startups backed
5stages
$4.0Braised between them
Series Abiggest stage
Series A
10
Funding by segment
- Series A$950M10
- Stage not reported$1.1B8
- Series C and later$1.2B8
- Series B$489M4
- Growth$173M2
Where they are based
- United States28$3.8B
- United Kingdom2$150M
- Canada1$5.1M
United States
United Kingdom
CanadaFounded
19Earlier
12
113
114
215
16
17
118
119
20
21
22
23
24
25
26
7 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M1
- $10M to $50M7
- $50M to $250M20
- $250M to $1B4
- $1B and over0
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
25 of 32 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States28
- United Kingdom2
- Canada1
Startups by country, 3 countries in all.
Segment by segment
Series A
10 startups · $950M raised
Rhythm PharmaceuticalsRhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeuticsUnited States$311M- COCullinan OncologyUnited States$150M
AstronauTxAstronauTx Ltd.United Kingdom$124M- CTCoDa TherapeuticsUnited States$78M
OncorusOncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.United States$77M- 2T27-8 TherapeuticsUnited States$65M
- TTTripley TherapeuticsUnited States$59M
- WTWereworld TherapeuticsUnited States$56M
Stage not reported
8 startups · $1.1B raised
EpizymeEpizyme is a biopharmaceutical company focusing on treatments for blood cancer and tumors.United States$332M
EndoGastric SolutionsEndoGastric Solutions is a medical device company based in Redmond, Washington.United States$293M
CelladonCelladon is a biotechnology company developing molecular therapies for the treatment of heart failure.United States$172M
True North TherapeuticsTrue North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases.United States$142M- CTCellerant TherapeuticsCellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies.United States$96M
- NPNeuroTherapeutics PharmaNeuroTherapeutics Pharma is a biopharmaceutical company developing new therapies to treat pain, epilepsy, and other nervous system disorder.United States$58M
- CSCHF SolutionsCHF Solutions designs and manufactures a device to remove excess fluid from patients suffering from fluid overload.United States$23M
- ITIntraLuminal TherapeuticsIntraLuminal Therapeutics provides products for interventional cardiologists and radiologists to recanalize totally occluded arteries.-$20M
Series C and later
8 startups · $1.2B raised
23andMeUnited States$729M- PSPerlegen SciencesPerlegen Sciences develops genetic variations providing physicians with information to improve the clinical process and treatment outcomes.United States$104M
Integrated DiagnosticsIntegrated Diagnostics develops tools to help physicians diagnose complex diseases with a non-invasive blood test.United States$95M
Frontier MedicinesFrontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.United States$87M
CeregeneCeregene is a biotechnology company that treats neurodegenerative disorders using the delivery of nervous system growth factors.United States$72M- AAmphivenaUnited States$62M
- ITIconic TherapeuticsUnited States$38M
- OOxagenOxagen develops small molecule drugs to treat inflammatory and respiratory diseases.United Kingdom$27M
Series B
4 startups · $489M raised
Semma TherapeuticsSemma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.United States$158M
Cardiac DimensionsCardiac Dimensions is a medical device company based in Kirkland, Washington, founded in 2001.United States$150M- HTHarpoon TherapeuticsHarpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.United States$145M
- AAllozyneAllozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.United States$37M
Growth
2 startups · $173M raised
TercicaTercica, a biotechnology company, develops and commercializes therapeutics for the treatment of endocrine and metabolic diseases.United States$149M
Clinical InkClinical Ink develops electronic documents recording software for recording source data on mobile devices during clinical trials.United States$24M
How this map is made. Every startup here works in Biotech and has raised money in a round we track that names MPM Capital as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosCo-investorsWho invests with MPM Capital39 co-investorsSector portfolioRA Capital Management's Biotech portfolio197 startups · $38BSector portfolioOrbiMed's Biotech portfolio176 startups · $28BSector portfolioPioneer Fund's AI portfolio171 startups · $2.8BSector portfolioGaingels' AI portfolio146 startups · $14BSector portfolioCormorant Asset Management's Biotech portfolio95 startups · $21B
Raising from investors like MPM Capital?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.